Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Change in Accured Expenses: 2015-2025

Historic Change in Accured Expenses for Seres Therapeutics (MCRB) over the last 11 years, with Sep 2025 value amounting to $633,000.

  • Seres Therapeutics' Change in Accured Expenses rose 106.96% to $633,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.1 million, marking a year-over-year decrease of 147.60%. This contributed to the annual value of -$10.2 million for FY2024, which is 164.38% down from last year.
  • Seres Therapeutics' Change in Accured Expenses amounted to $633,000 in Q3 2025, which was up 279.83% from -$352,000 recorded in Q2 2025.
  • Seres Therapeutics' 5-year Change in Accured Expenses high stood at $38.6 million for Q3 2021, and its period low was -$19.0 million during Q1 2023.
  • In the last 3 years, Seres Therapeutics' Change in Accured Expenses had a median value of -$1.1 million in 2023 and averaged $134,636.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first soared by 6,495.04% in 2023, then slumped by 756.87% in 2024.
  • Seres Therapeutics' Change in Accured Expenses (Quarterly) stood at $65,000 in 2021, then spiked by 520.00% to $403,000 in 2022, then skyrocketed by 6,495.04% to $26.6 million in 2023, then slumped by 126.12% to -$6.9 million in 2024, then surged by 106.96% to $633,000 in 2025.
  • Its last three reported values are $633,000 in Q3 2025, -$352,000 for Q2 2025, and -$4.4 million during Q1 2025.